文献速递膀胱癌与上尿路尿路上皮癌

低级别膀胱肿瘤治疗降阶:国际膀胱癌组织(IBCG)协作综述

Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG).
PubMed 文献 · Eur Urol Oncol · 2024-08-31

国际膀胱癌组织(IBCG)对PubMed/MEDLINE和Cochrane CENTRAL数据库进行协作综述,聚焦复发性低级别Ta期非肌层浸润性膀胱癌的降阶治疗策略。综述认为主动监测、化学消融和门诊电灼是有效选择,可降低并发症率、发病率、医疗费用并改善生活质量,且不损害肿瘤学安全性。IBCG推荐对经仔细选择的患者使用这些方法。

要点

  • 主动监测、化学消融和门诊电灼是复发性低级别Ta期非肌层浸润性膀胱癌的有效治疗选择。
  • 与经尿道膀胱肿瘤电切术相比,这些降阶方法并发症率更低、发病率更低、医疗费用更低且生活质量更好。
  • IBCG推荐对经仔细选择的患者使用这些降阶方法以降低医疗费用并提高生活质量。

核心结论

  • 综述表明,对复发性低级别Ta期非肌层浸润性膀胱癌采用强度较低的治疗策略既可行又有价值。
  • IBCG推荐对经仔细选择的患者使用这些方法,以帮助降低医疗费用并提高患者生活质量。

研究设计与样本

  • IBCG在PubMed/MEDLINE和Cochrane CENTRAL数据库中进行协作综述,聚焦随机对照试验、系统综述和Meta分析等高质量证据,并回顾了重要泌尿外科协会发布的指南。

主要发现

  • 主动监测、化学消融和门诊电灼是复发性低级别Ta期非肌层浸润性膀胱癌的有效治疗选择。
  • 与经尿道膀胱肿瘤电切术相比,这些降阶方法并发症率更低、发病率更低、医疗费用更低且患者生活质量更好。
  • 这些获益是在不损害肿瘤学安全性的情况下实现的。

关键数值与推荐

  • IBCG推荐对经仔细选择的复发性低级别Ta期非肌层浸润性膀胱癌患者使用主动监测、化学消融或门诊电灼等降阶治疗。

临床怎么用

  • IBCG推荐对经仔细选择的复发性低级别Ta期非肌层浸润性膀胱癌患者使用主动监测、化学消融或门诊电灼,以降低医疗费用并提高生活质量。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Management of low-grade (LG) urothelium-confined (Ta stage) non-muscle-invasive bladder cancer (NMIBC) poses a distinct therapeutic challenge. Transurethral resection of bladder tumor (TURBT), the standard treatment, frequently has to be repeated because of high tumor recurrence rates. This places a considerable strain on both patients and health care infrastructure, underscoring the need for alternative management approaches. Herein, the IBCG (International Bladder Cancer Group), conducted a review to explore the efficacy and safety of deintensified treatment strategies for recurrent LG Ta NMIBC. METHODS: We conducted a collaborative review of relevant literature in the PubMed/MEDLINE and Cochrane CENTRAL databases. Our focus was on high-quality evidence, including randomized controlled trials, systematic reviews, and meta-analyses. We also reviewed guidelines published by prominent urological associations. KEY FINDINGS AND LIMITATIONS: Active surveillance, chemoablation, and office fulguration are valid treatment options for recurrent LG Ta NMIBC. These deintensified approaches offer several advantages over TURBT: lower complication rates, less morbidity, lower health care costs, and better quality of life for patients. Importantly, these benefits are achieved without compromising oncological safety. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our review demonstrates that less intensive treatment strategies for recurrent LG Ta NMIBC are both feasible and valuable. The IBCG recommends use of these approaches for carefully selected patients to help lower health care costs and enhance patients' quality of life. PATIENT SUMMARY: We reviewed studies on less invasive management options for low-grade noninvasive bladder cancer, including active surveillance, chemical ablation, and heat treatment. Recent results confirm that these less intense treatment options can reduce the treatment burden and costs for patients and preserve their quality of life without negatively affecting cancer control outcomes.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Contieri R, Soloway MS, Gontero P, et al. Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG). Eur Urol Oncol. 2024. PMID: 39218742. doi:10.1016/j.euo.2024.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。